ClinicalTrials.gg
RecruitingNCT03865914Updated Mar 31, 2022

Correlation Study Between Clinical Phenotype and Pathology of Type 2 Diabetic Nephropathy

An observational study in Diabetic Kidney Disease, sponsored by Chinese PLA General Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by Chinese PLA General Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2017; still recruiting 8 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Diabetic Nephropathies with a site in China — 22 open to participants now, 30 under way, none of them phase 3. Diabetic Nephropathies · China.

Planned enrollment
5th of 22
2,000 · median 620
Started
2017
with 4 others
Observational
22 of 75
10 open now
Primary completion
2027-11
later than 21 of 29 live
Registered
25th of 75
by date
Lead sponsor
4 of 75
Chinese PLA General Hospital

Among the 75 studies in Diabetic Nephropathies with a site in China, this one is the 5th largest by planned enrollment of the 22 observational ones that give a count, is one of 5 that started in 2017, is one of 22 observational ones, reaches primary completion later than 21 of the 29 other live ones, and was the 25th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 75 studies in Diabetic Nephropathies with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Diabetic Nephropathies with a site in China, or all of them as a file.
02

Study summary

With the rapid increase of diabetic nephropathy worldwide, type 2 diabetes mellitus(DM) is the leading cause of end-stage renal disease(ESRD). Pathological types of diabetic kidney disease(DKD) could be mainly divided into diabetic nephropathy(DN)and non-diabetic renal diseases(NDRD). There are no accurate renal biopsy indications and standardized operation procedures for type 2 diabetic nephropathy. The clinical stages of type 2 diabetic nephropathy still referred to the Mogensen stage of type 1 diabetic nephropathy. Thus, our study aim to clarify the differences in clinical phenotype between type 2 DN and type 2 NDRD, analysis the correlation between clinical and pathological features, and offer the criteria for clinical staging and prognosis.

03

Conditions studied

  • Diabetic Kidney Disease

Keywords

  • Diabetic kidney disease (DKD)
  • Diabetic nephropathy(DN)
  • non-diabetic renal diseases( NDRD)
  • Clinical-pathological correlations
  • differential diagnosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The aim of this study is to clarify the differences in clinical phenotype between type 2 DN and type 2 NDRD, analysis the correlation between clinical and pathological features, and offer the criteria for clinical staging and prognosis.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age≥18, male or female
  • Clinical diagnosed as type 2 diabetes mellitus
  • The presence of renal impairment including: microalbuminuria or overt proteinuria or renal insufficiency
  • The renal was performed with complete renal pathological diagnosis
  • Obtaining the signed from patients

Exclusion criteria

Exclusion Criteria:

  • The history of the disease was not complete
  • Clinical diagnosed as other secondary renal diseases
  • Patients with hereditary kidney disease
  • diseases
  • Patients with malignant tumor were expected to survive less than 6 months
  • Pregnancy and lactation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Type 2 diabetic nephropathy

    The cohort will be followed for at least 10 years. The cohort will be divided into 2 groups according the pathological results of patients,and at least 3 groups according to clinical features such as renal function and proteinuria.

06

What researchers measure

Primary outcomes

  1. change in eGFR and urine protein from baseline

    eGFR is calculated using the CKD-EPI formula, involving gender, age, and serum creatinine.

    Time frame: 24months

07

Study locations

1 of 1 sites recruiting
  • Chinese PLA General Hospital
    Beijing, Beijing 100853, China
    Recruiting
    • Xiangmei Chen, MD.&Ph.D · Contactxmchen301@126.com · +86 010 66935462
    • Qian Wang, MM · Contact794317255@qq.com · +86 010 66935462
    • Xiangmei Chen, MD.&Ph.D · Principal investigator
    • Zheyi Dong, MD.&Ph.D · Sub investigator
08

References and documents

Publications

  • Zhang W, Liu X, Dong Z, Wang Q, Pei Z, Chen Y, Zheng Y, Wang Y, Chen P, Feng Z, Sun X, Cai G, Chen X. New Diagnostic Model for the Differentiation of Diabetic Nephropathy From Non-Diabetic Nephropathy in Chinese Patients. Front Endocrinol (Lausanne). 2022 Jun 30;13:913021. doi: 10.3389/fendo.2022.913021. eCollection 2022. PubMed 35846333 ↗
  • Qu YL, Dong ZY, Cheng HM, Liu Q, Wang Q, Yang HT, Mao YH, Li JJ, Liu HF, Geng YQ, Huang W, Liu WH, Xie HD, Peng F, Li S, Jiang SS, Li WZ, Duan SW, Feng Z, Zhang WG, Liu YN, Tian JZ, Chen XM. Evaluation of Renal Impairment in Patients with Diabetic Kidney Disease by Integrated Chinese and Western Medicine. Chin J Integr Med. 2023 Apr;29(4):308-315. doi: 10.1007/s11655-022-3520-0. Epub 2022 Jun 9. PubMed 35679002 ↗

Individual participant data

Plan to share: No — The test has not been completed.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2017 (actual). Primary completion is estimated for Nov 2027, 120 months after the start.

Of 38 observational studies under Diabetic Nephropathies, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 25. This study's planned 120 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2019
First posted
Mar 7, 2019
StartActual
Nov 30, 2017
Primary completionEst.
Nov 30, 2027
CompletionEst.
Dec 31, 2030
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03865914
Collaborators
Beijing Municipal Science & Technology Commission, China-Japan Friendship Hospital, Beijing Friendship Hospital, Beijing Hospital, Fourth Medical Center of PLA General Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Third Medical Center of PLA General Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, The First Affiliated Hospital of Dalian Medical University, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Dongzhimen Hospital, Beijing, Shanghai University of Traditional Chinese Medicine
Responsible party
Xiangmei Chen (Professor,Chief physician,Academician of Chinese Academy of Engineering, Chinese PLA General Hospital) — Principal investigator
First posted
Mar 7, 2019
Start date
Nov 30, 2017
Primary completion
Nov 30, 2027 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Mar 31, 2022

Study contacts

Xiangmei Chen, MD.&Ph.D
Contact
xmchen301@126.com
+86 010 66935462
Zheyi Dong, MD.&Ph.D
Contact
shengdai26@163.com
+86 010 66935462
Xiangmei Chen, MD.&Ph.D
principal investigator · Chinese PLA General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion